275 WYMAN STREET, WALTHAM, MA
2026 Annual Meeting Results; Directors Elected at Cogent Biosciences
Reports Recent Business Highlights and First Quarter 2026 Financial Results
Annual Report to Security Holders
Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Other Events
Cogent Biosciences Completes $230 Million Convertible Notes Offering
Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
Investor Presentation
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus